Vor Biopharma Inc. 8-K Filing
Ticker: VOR · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $8.18, $17.80, $47.60 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vor Biopharma Inc. (ticker: VOR) to the SEC on Dec 9, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob); $8.18 (the " Inducement Plan ") was reduced to $8.18 per share (the " Reduced Exercise Price); $17.80 (iously had exercise prices ranging from $17.80 to $47.60 per share. The Repriced Opt); $47.60 (exercise prices ranging from $17.80 to $47.60 per share. The Repriced Options inclu).
How long is this filing?
Vor Biopharma Inc.'s 8-K filing is 3 pages with approximately 1,007 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,007 words · 4 min read · ~3 pages · Grade level 14.2 · Accepted 2025-12-09 07:58:39
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $8.18 — the " Inducement Plan ") was reduced to $8.18 per share (the " Reduced Exercise Price
- $17.80 — iously had exercise prices ranging from $17.80 to $47.60 per share. The Repriced Opt
- $47.60 — exercise prices ranging from $17.80 to $47.60 per share. The Repriced Options inclu
Filing Documents
- vor-20251205.htm (8-K) — 51KB
- 0001193125-25-311957.txt ( ) — 156KB
- vor-20251205.xsd (EX-101.SCH) — 24KB
- vor-20251205_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: December 9, 2025 By: /s/ Jean-Paul Kress Name: Jean-Paul Kress Title: Chief Executive Officer